Manuscript Number: EJCMI-D-09-00590R2

Title: Serotype distribution in pneumococcal acute otitis media with ruptured tympanic membrane or sepsis in Germany

Article Type: Review

Keywords: pneumococcal conjugate vaccines; Streptococcus pneumoniae; acute otitis media; Germany

Corresponding Author: Dr Mark van der Linden,

Corresponding Author's Institution: University Hospital RWTH Aachen

First Author: Mark van der Linden

Order of Authors: Mark van der Linden; Ralf R Reinert

Abstract: This retrospective analysis examined the pneumococcal serotype distribution of acute otitis media in Germany from 1995 to 2007. Data from the German National Reference Centre for Streptococci included 512 cases of pneumococcal otitis media in children and adults. Infections were mainly seen in children aged <5 years, who represented 67.0% of all reported cases. Most isolates (86.7%) were from spontaneous ruptures of the tympanum; 11.1% of the isolates were from otogenic sepsis or meningitis. Serotype 19F was the leading serotype (21.5%); serotype 3 (13.9%) was also often encountered. In children aged <5 years, the 7-valent, 10-valent, and 13-valent pneumococcal conjugate vaccines covered 54.3%, 60.2%, and 84.6% of the serotypes, respectively. Reduced penicillin susceptibility (minimum inhibitory concentration ≥ 0.1 mg/L) was seen in 11.0% of strains; 22.4% of strains were resistant to macrolides. Although based on a very limited selection of acute otitis media isolates, this analysis provides an estimate of the pneumococcal serotypes responsible for otitis media in Germany and underscores the need for future prospective studies.

Ref.: Ms. No. EJCMID-D-09-00590

Serotype distribution in pneumococcal acute otitis media with ruptured tympanic membrane or sepsis in Germany

European Journal of Clinical Microbiology & Infectious Diseases

Dear Dr van der Linden,

Reviewers have now commented on your paper. You will see that they are advising that you revise your manuscript.

For your guidance, reviewers' comments are appended below.

If you decide to revise the work, please submit a list of changes or a rebuttal against each point which is being raised when you submit the revised manuscript.

Your revision is due by 03-03-2010.

To submit a revision, go to <http://ejcmid.edmgr.com/> and log in as an Author. You will see a menu item call Submission Needing Revision. You will find your submission record there.

Yours sincerely

Alex van Belkum

Editor-in-Chief

European Journal of Clinical Microbiology & Infectious Diseases

Reviewers' comments:

Reviewer #1: This is an important collection of AOM isolates. Such collections are rare since in most countries no central collection of AOM isolates exists. Therefore, despite several important limitations of the study, some of which are recognized by the authors and some of which I have added, this set of data is important. At least serotypes associated with complicated otitis media can be assumed from this collection.

I. Abstract

1) Please provide the years of the study.

We thank the reviewer for this comment. We have added the years of the study (1995-2007) to the abstract.

2) You need to recognize already at the abstract level that this represents an important, but very selective series of isolates (since it is mainly or at least commonly non-responsive AOM, recurrent AOM, complicated AOM or invasive cases)

We agree with the reviewers and have added the following sentence to the abstract: 'Although based on a very limited selection of acute otitis media isolates,....'

II. Introduction

1) First page of the introduction lines, 14-15: There are new and more detailed references for the statement that serotypes are important in AOM (eg. Shouval et al, PIDJ 2009;28:277-282; Aguilar et al, J Pediatr Otolaryngol 73:1407-1411, 2009; Rodgers et al, Vaccine 27:3802-10, 2009).

The reviewer is right and we have added these more recent references to the text.

III. Results

1) The inclusion of *S. pneumoniae* isolated from blood and CSF is probably not appropriate since you do not have the proof that the otitis media was pneumococcal otitis media. I believe this should be excluded.

Even though it was not microbiologically proven that AOM patients with pneumococci isolated from invasive material suffered from pneumococcal otitis, this is very likely. To emphasize this point we have added the following sentence to the manuscript: 'Even though it is highly likely that these children suffered from pneumococcal AOM, this was not microbiologically confirmed in all cases.'

2) Figure 1: Please instead of 2 categories "all ages" and "<5 years" modify those to "<5 years" and ">= 5 years".

We have modified Table 2 according to the reviewers' comments. Furthermore we have changed the age cohorts accordingly (0 - <2, >=2 - <5, >=5 - <16, >=16) throughout the whole text and recalculated all corresponding values for coverage, serotypes, MICs, etc. as well as Figure 2.

3) Table 2 and text" Coverage by PCV7, PCV10 and PCV13: Some assumptions with regard to coverage of PCV7 and PCV10 against 6A must be made.

All coverage data were calculated without assuming any cross-protection. A remark stating this explicitly concerning serotype 6A was added to the text: 'The coverage calculations were performed without accounting for possible cross-protection of serotype 6B towards serotype 6A, as described in some reports on PCV7 and the 10-valent vaccine'.

4) This study does not really represent all cases of AOM, but rather selected population with complicated AOM.

Therefore, the findings may not necessarily compare to other studies, many of which also have their own selection.

We fully agree with the reviewer regarding the limitations of this study, and that is why we have explicitly mentioned them in the discussion and also in the Abstract (see comment 1, 2)

**Serotype distribution in pneumococcal acute otitis media with ruptured tympanic
membrane or sepsis in Germany**

M. van der Linden, R. R. Reinert

Corresponding author:

M. van der Linden

National Reference Centre for Streptococci

Department of Medical Microbiology

University Hospital RWTH Aachen

Pauwelsstr. 30

52074 Aachen, Germany

Phone: +49 241 8089946

Fax: +49 241 8082483

E-mail: mlinden@ukaachen.de

R. R. Reinert

Pfizer Inc, formerly Wyeth Vaccines Research

Paris La Défense

Paris, France

Target journal: *EJCMID*

Abstract This retrospective analysis examined the pneumococcal serotype distribution of acute otitis media in Germany from 1995 to 2007. Data from the German National Reference Centre for Streptococci included 512 cases of pneumococcal otitis media in children and adults. Infections were mainly seen in children aged <5 years, who represented 67.0% of all reported cases. Most isolates (86.7%) were from spontaneous ruptures of the tympanum; 11.1% of the isolates were from otogenic sepsis or meningitis. Serotype 19F was the leading serotype (21.5%); serotype 3 (13.9%) was also often encountered. In children aged <5 years, the 7-valent, 10-valent, and 13-valent pneumococcal conjugate vaccines covered 54.3%, 60.2%, and 84.6% of the serotypes, respectively. Reduced penicillin susceptibility (minimum inhibitory concentration ≥ 0.1 mg/L) was seen in 11.0% of strains; 22.4% of strains were resistant to macrolides. Although based on a very limited selection of acute otitis media isolates, this analysis provides an estimate of the pneumococcal serotypes responsible for otitis media in Germany and underscores the need for future prospective studies.

Abstract Word Count: 166

Keywords: pneumococcal conjugate vaccines, *Streptococcus pneumoniae*, acute otitis media, Germany

Text Word Count: Approximately 1850

Introduction

Streptococcus pneumoniae is a major pathogen in cases of acute otitis media (AOM), along with *Haemophilus influenzae* and *Moraxella catarrhalis* [1]. Of these three organisms, *S. pneumoniae* has been associated with more severe AOM signs and symptoms, greater virulence, and more complications [2]. To date, 91 distinct serotypes of *S. pneumoniae* have been identified, but only a few are responsible for most cases of AOM in young children, including serotypes 3, 6B, 9V, 14, 19F, and 23F [3, 4].

The currently approved seven-valent pneumococcal conjugate vaccine (PCV7; Prevnar[®]/Prevenar[®] [Pfizer Inc, Philadelphia, PA]) includes purified capsular polysaccharides of seven serotypes of *S. pneumoniae* (4, 6B, 9V, 14, 18C, 19F, and 23F) conjugated to mutant diphtheria toxoid cross-reactive material (CRM)₁₉₇. In prelicensure trials, PCV7 demonstrated almost 100% efficacy against invasive pneumococcal disease (IPD) and some efficacy against AOM [5]. In the Northern California Kaiser Permanente trial in the USA ($n=37,868$ infants), PCV7 was 7% efficacious in preventing episodes of otitis media [5]. In the Finnish Otitis Media (FinOM) trial ($n=1,662$ infants), efficacy against AOM from any cause was 6% [6]. Long-term follow-up of these cohorts confirmed that receipt of PCV7 in infancy was associated with fewer otitis media physician visits and episodes [7] and a reduction in tympanostomy tube placement in children aged <12 months to 4–5 years [7, 8].

In a more recent publication, Shouval et al. reported that in children aged <3 years in Israel, PCV7, 10-valent vaccine, and 13-valent vaccine provided coverage of AOM of 54%, 59%, and 79%, respectively [9]. In a review by Rodgers et al., serotypes 6A, 6B, 14, 19A, 19F, and 23F were described as the most common serotypes in pneumococcal AOM among children worldwide [10].

1 Although vaccine trials with PCV7 showed modest efficacy against AOM overall,
2 there was considerable variation in serotype-specific efficacy. In the FinOM trial, PCV7
3 reduced the incidence of AOM due to vaccine serotypes by 57% overall. However, efficacy
4 for specific serotypes ranged from 25% for serotype 19F to 84% for serotype 6B [6].
5
6

7
8
9 Following generalized vaccination with PCV7 in the USA, at least three studies
10 reported on the impact of immunization on the microbiology of AOM. These studies
11 analyzed pre- and post-vaccination rates of middle-ear fluid (MEF) pathogen isolates and
12 found that community use of PCV7 significantly reduced the overall proportion of *S.*
13 *pneumoniae* isolates and vaccine serotypes causing AOM [11–13]. Data from the USA
14 demonstrated that in a comparison of 2004 and 1997–1999 (baseline period), rates of
15 ambulatory visits and antibiotic prescriptions attributable to AOM decreased by 42.7% and
16 41.9%, respectively [14]. Notably, the proportion of AOM infections due to nonvaccine
17 pneumococcal strains and serogroups 6 and 19 increased over time [11, 13].
18
19

20
21 In July 2006, the German Ständige Impfkommision (permanent committee on
22 vaccination, STIKO) recommended vaccination with PCV7 for all children aged <2 years
23 [15]. However, little is known about the epidemiology of pneumococcal otitis media in
24 Germany [10, 16], and no recent data are available on the serotype distribution of
25 pneumococcal isolates from German children and adults with otitis media. Therefore, our
26 study examined the pneumococcal serotype distribution related to AOM, using data from the
27 German National Reference Centre for Streptococci.
28
29
30

31 **Materials and methods**

32
33 The database of the German National Reference Centre for Streptococci, which contains
34 information on more than 25,000 cases of pneumococcal infections, was searched for cases of
35 pneumococcal otitis media that occurred between 1995 and 2007. All *S. pneumoniae* isolates
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

from ear swab and other isolates with the clinical diagnosis “acute otitis” or “mastoiditis” were included in the study. Duplicate isolates were excluded from the analysis.

Strains were obtained from (1) the study of IPD in children performed on a nationwide basis in Germany since 1996 (collaboration between the Robert Koch Institute, the ESPED [Erhebungseinheit für Seltene Pädiatrische Erkrankungen in Deutschland], and the National Reference Centre for Streptococci) [17–22], and (2) the nation-wide surveillance of IPDs in adults [23] and upper respiratory tract infections in children and adults [17]. All studies were summarized in one database and made available for analysis.

Pneumococcal isolates were identified with standard microbiology methods, such as determination of optochin susceptibility and bile solubility. Strains were typed using the antisera provided by the Statens Serum Institut in Copenhagen, Denmark. A subgroup of all strains was tested for antibiotic sensitivity to penicillin G and clarithromycin (macrolide) using the Clinical and Laboratory Standards Institute (CLSI) guidelines for susceptibility testing [24].

Results

A total of 512 isolates, mainly from children aged <2 years (34.4%), were included in the study. The remainder were from children aged ≥ 2 to <5 years (32.6%); ≥ 5 to <16 years (22.5%); and adults aged ≥ 16 years (10.5%). Sources of pneumococcal isolates are presented in **Table 1**. Most cases (444 strains; 86.7% of isolates) were from children with spontaneous rupture of the tympanum (specimen = pus from the middle ear or ear swab). In addition, three isolates from puncture of the mastoid and eight isolates from tympanocentesis were included in the study. There were 57 isolates (11.1%) from invasive disease (sepsis and meningitis). Even though it is highly likely that these children suffered from pneumococcal AOM, this

was not microbiologically confirmed in all cases. Infections were more often seen in males (54.5% of strains).

Serotype data for all strains are presented in **Figure 1**. In our study, 19F was the leading serotype (21.5%), followed by serotypes 3 (13.9%), 14 (10.5%), and 23F (10.0%).

Among children aged <5 years, the leading serotype was 19F (24.5%), followed by serotypes 14 (12.2%), 23F (11.4%), and 3 (8.7%) (**Figure 1**).

Coverage by serotypes included in the current and investigational pneumococcal conjugate vaccine formulations was evaluated. These formulations include PCV7 (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F); the 10-valent vaccine (PCV7 serotypes plus serotypes 1, 5, and 7F); and the investigational 13-valent vaccine (10-valent vaccine serotypes plus serotypes 3, 6A, and 19A). Coverages of the 7-valent, 10-valent, and investigational 13-valent pneumococcal conjugate vaccines in isolates from pneumococcal AOM with ruptured tympanic membrane or sepsis in Germany are presented in **Table 2**. The coverage calculations were performed without accounting for possible cross-protection of serotype 6B towards serotype 6A, as described in some reports on PCV7 and the 10-valent vaccine [25, 26]. For children aged <5 years, coverage of PCV7 was 60.3% ($n=207$); the 10-valent vaccine, 63.6% ($n=218$); and the 13-valent vaccine, 85.4% ($n=293$). The cumulative coverage of the different pneumococcal conjugate vaccine formulations is presented in **Figure 2**.

Antibiotic susceptibility data were available for 456 isolates. Reduced susceptibility to penicillin was seen in 11.0% of strains. This included a relatively high rate of strains (4.4%) with high-level penicillin G resistance (minimum inhibitory concentration [MIC] ≥ 2 mg/L). The rate of resistance to macrolides (clarithromycin) was 22.4% (**Table 3**). Antibiotic susceptibility data were available for 304 strains isolated from children aged <5 years; 9.5% and 24.0% of these strains were found to be nonsusceptible to penicillin G and clarithromycin, respectively.

Characteristics of IPD in 33 children with otitis media (otogenic sepsis or meningitis) are presented in **Table 4**. These cases were mainly seen in very young children (aged ≤ 1 year). The collection included 13 cases diagnosed from cerebrospinal fluid and 20 cases from blood. Among these infections, serotype 14 was the most common serotype (14 cases) followed by serotype 19A (4 cases). Serotype 19A is not included in PCV7 or the 10-valent pneumococcal conjugate vaccine. Of note, macrolide resistance was relatively common in those cases and occurred in more than a third of isolates.

Discussion

This study presents data on the serotype distribution of pneumococcal isolates from children and adults with spontaneously draining otitis media in Germany. The analysis included 512 cases, with 67.0% occurring in children aged < 5 years. The results showed a relatively high rate of serotype 19F infections (21.5%), which is in accordance with the serotype distribution found in recent clinical studies and postlicensure surveillance of AOM in children in Finland [6], the Czech-Republic [27], and the USA [28]. However, some differences in serotype distribution, particularly regarding serotype 23F infections, were noted in the German data compared with distribution data from other countries.

A 2002 retrospective study, for example, analyzed nine geographically diverse data sets comprising pneumococcal isolates from MEF samples collected from children with AOM [28]. Samples were collected between 1994 and 2000 from 3,232 children in the USA, Argentina, Finland, France, Greece, Israel, and several Eastern European countries. The results showed that the most common serotypes in each data set and age group tended to be the same, despite variations in location, data-set design, and antibiotic resistance. Serotypes 23F, 19F, and 14 were most prominent, each comprising about 13% to 16% of the overall data set [28]. Serotypes 6B, 6A, 19A, and 9V were less common, each comprising about 5%

1 to 10% of all data sets. Serotypes 1, 5, and 7 contributed little (<2%) to overall pneumococcal
2 AOM. Serotype 3 represented about 4% of the overall serotypes, and was most prominent in
3 the youngest (<6 months) and oldest (≥ 60 months) age groups (approximately 5.8% and
4 21.5% of all isolates, respectively) [28].

5
6
7
8
9 In contrast to these observations, our analysis of data from German children and
10 adults showed a lower rate of serotype 23F infections (10.0%) and a higher rate of serotype 3
11 infections (13.9%). Globally, serotype 3 has become an increasingly significant MEF
12 pathogen in children [10]. In German children aged <5 years, serotype 3 was found in 8.7%
13 of cases. The coverage for the serotypes included in PCV7 (recommended for general use in
14 children aged <2 years in Germany) was 60.3%, which was lower than the serotype coverage
15 previously reported for IPD in Germany [18]. The inclusion of serotypes 1, 5, and 7F, which
16 are in the 10-valent pneumococcal conjugate vaccine, increases the coverage by 3.3% to
17 63.6%. The investigational 13-valent vaccine, which includes serotypes 3, 6A, and 19A in
18 addition to the 10-valent vaccine serotypes, increases the coverage to 85.4%, mainly due to
19 the inclusion of serotypes 3 and 19A (Figure 2).

20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36 Interestingly, we found a relatively high rate of reduced penicillin susceptibility
37 (11.0%) in the present study. This rate was higher than that previously reported with invasive
38 disease in German children [18]. In addition, we found a high rate of macrolide resistance
39 (22.4%), in accordance with rates reported for IPD in children in Germany [18, 19]. These
40 high resistance rates may reflect the complexity of many of the cases, which included otitis
41 media therapy failures.

42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65 Our study has some limitations. First, it covers a long period of time, and the power is
low. Admittedly, more patients and data would have been useful for our analysis—
unfortunately we had no control over the number of the study population and were forced to
rely only on the AOM serotype data available for Germany at the time of the study. A second

1 limitation is the fact that microbiological diagnosis is not done on a routine basis in Germany.
2
3 Consequently, the incidence of AOM in Germany is probably under-reported, because only a
4
5 portion of the thousands of children who contract AOM in Germany each year are tested.
6
7 Mild IPD may be under-diagnosed in several European countries, because blood cultures are
8
9 not usually ordered for outpatients, who may be treated with no documentation of their
10
11 febrile episodes. Blood cultures may not be ordered for inpatients with fever without focus or
12
13 with pneumonia [29]. Lastly, pneumococcal isolates used in our study were identified with
14
15 standard microbiology methods. Use of more specific techniques, such as polymerase chain
16
17 reaction (PCR), would have improved identification of otitis media-associated bacteria.
18
19
20
21

22 Despite these limitations, our retrospective analysis of pneumococcal strains gathered
23
24 the data needed to provide a rough estimate of the pneumococcal serotypes that cause otitis
25
26 media associated with spontaneous drainage in Germany. This information will be invaluable
27
28 when planning vaccination strategies to protect against otitis media.
29
30
31
32
33

34 **Acknowledgements** Medical writing support for this manuscript was provided by Prasad
35
36 Kulkarni of Excerpta Medica (Bridgewater, NJ), and was funded by Wyeth, which was
37
38 acquired by Pfizer Inc in October 2009.
39
40
41
42
43

44 **Conflicts of Interest** Dr Reinert is an employee of Pfizer Inc. Dr van der Linden has been a
45
46 member of advisory boards for Wyeth and GlaxoSmithKline, and has received invitations to
47
48 scientific conferences from Wyeth and GlaxoSmithKline.
49
50
51
52
53

54 **References**

- 55 1. Fletcher MA, Fritzell B (2007) Brief review of the clinical effectiveness of
56
57 PREVENAR[®] against otitis media. Vaccine 25:2507–2512
58
59
60
61
62
63
64
65

2. Palmu AAI, Herva E, Savolainen H, Karma P, Makela PH, Kilpi TM (2004)
Association of clinical signs and symptoms with bacterial findings in acute otitis
media. Clin Infect Dis 38:234–242
3. Block SL, Hedrick J, Harrison CJ, Tyler R, Smith A, Findlay R, Keegan E (2002)
Pneumococcal serotypes from acute otitis media in rural Kentucky. Pediatr Infect Dis
J 21:859–865
4. Butler JC, Breiman RF, Lipman HB, Hofmann J, Facklam RR (1995) Serotype
distribution of *Streptococcus pneumoniae* infections among preschool children in the
United States, 1978–1994: implications for development of a conjugate vaccine. J
Infect Dis 171:885–889
5. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L, Ensor KM,
Hackell J, Siber G, Malinoski F, Madore D, Chang I, Kohberger R, Watson W,
Austrian R, Edwards K (2000) Efficacy, safety and immunogenicity of heptavalent
pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente
Vaccine Study Center Group. Pediatr Infect Dis J 19:187–195
6. Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, Takala A, Kayhty H,
Karma P, Kohberger R, Siber G, Makela PH (2001) Efficacy of a pneumococcal
conjugate vaccine against acute otitis media. N Engl J Med 344:403–409
7. Fireman B, Black SB, Shinefield HR, Lee J, Lewis E, Ray P (2003) Impact of the
pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J 22:10–16
8. Palmu AAI, Verho J, Jokinen J, Karma P, Kilpi TM (2004) The seven-valent
pneumococcal conjugate vaccine reduces tympanostomy tube placement in children.
Pediatr Infect Dis J 23:732–738

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
9. Shouval DS, Greenberg D, Givon-Lavi N, Porat N, Dagan R (2009) Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines. *Pediatr Infect Dis J* 28:277–282
10. Rodgers GL, Arguedas A, Cohen R, Dagan R (2009) Global serotype distribution among *Streptococcus pneumoniae* isolates causing otitis media in children: potential implications for pneumococcal conjugate vaccines. *Vaccine* 27:3802–3810
11. Block SL, Hedrick J, Harrison CJ, Tyler R, Smith A, Findlay R, Keegan E (2004) Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. *Pediatr Infect Dis J* 23:829–833
12. Casey JR, Pichichero ME (2004) Changes in frequency and pathogens causing acute otitis media in 1995-2003. *Pediatr Infect Dis J* 23:824–828
13. McEllistrem MC, Adams J, Mason EO, Wald ER (2003) Epidemiology of acute otitis media caused by *Streptococcus pneumoniae* before and after licensure of the 7-valent pneumococcal protein conjugate vaccine. *J Infect Dis* 188:1679–1684
14. Zhou F, Shefer A, Kong Y, Nuorti JP (2008) Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997–2004. *Pediatrics* 121:253–260
15. Claes C, Reinert RR, Vauth C, Greiner W (2008) Health Technology Assessment Heptavalenter Pneumokokkenkonjugat-Impfstoff (PCV7)
16. Ziebold C, von Kries R, Siedler A, Schmitt HJ (2000) Epidemiology of pneumococcal disease in children in Germany. *Acta Paediatr Suppl* 435:17–21

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
17. Reinert RR, Simic S, Al-Lahham A, Reinert S, Lemperle M, Lütticken R (2001)
Antimicrobial resistance of *Streptococcus pneumoniae* recovered from outpatients
with respiratory tract infections in Germany from 1998 to 1999: results of a national
surveillance study. J Clin Microbiol 39:1187–1189
 18. Reinert RR, van der Linden M, Seegmuller I, Al-Lahham A, Siedler A, Weissmann B,
Toschke AM, von Kries R (2007) Molecular epidemiology of penicillin-non-
susceptible *Streptococcus pneumoniae* isolates from children with invasive
pneumococcal disease in Germany. Clin Microbiol Infect 13:363–368
 19. Siedler A, Reinert RR, Toschke M, Al-Lahham A, von Kries R (2005) Regional
differences in the epidemiology of invasive pneumococcal disease in toddlers in
Germany. Pediatr Infect Dis J 24:1114–1115
 20. von Kries R, Hermann M, Al-Lahham A, Siedler A, Reinert RR (2002) Will the 7-
valent pneumococcal vaccine have a similar impact on all invasive pneumococcal
infections in children in Germany as in the Kaiser Permanente Trial? Eur J Pediatr
161:S140–S143
 21. von Kries R, Hermann M, Hachmeister A, Siedler A, Schmitt HJ, Al-Lahham A,
Reinert RR (2002) Prediction of the potential benefit of different pneumococcal
conjugate vaccines on invasive pneumococcal disease in German children. Pediatr
Infect Dis J 21:1017–1023
 22. von Kries R, Siedler A, Schmitt HJ, Reinert RR (2000) Proportion of invasive
pneumococcal infections in German children preventable by pneumococcal conjugate
vaccines. Clin Infect Dis 31:482–487

23. Reinert RR, Haupts S, van der Linden M, Heeg C, Cil MY, Al-Lahham A, Fedson DS
(2005) Invasive pneumococcal disease in adults in North-Rhine Westphalia,
Germany, 2001–2003. Clin Microbiol Infect 11:985–991
24. Clinical and Laboratory Standards Institute (2006) Performance standards for
antimicrobial disk susceptibility tests; approved standard—ninth edition. CLSI,
Wayne, Pa
25. Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, Nyquist
A-C, Gershman KA, Vazquez M, Bennett NM, Reingold A, Thomas A, Glode MP,
Zell ER, Jorgensen JH, Beall B, Schuchat A (2006) Effectiveness of seven-valent
pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched
case-control study. Lancet 368:1495–1502
26. Vesikari T, Wysocki J, Chevallier B, Karvonen A, Czajka H, Arsene J-P, Lommel P,
Dieussaert I, Schuerman L (2009) Immunogenicity of the 10-valent pneumococcal
non-typeable *Haemophilus influenzae* protein D conjugate vaccine (PHiD-CV)
compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 28:S66–S76
27. Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, Kohl I, Lommel
P, Poolman J, Prieels JP, Schuerman L (2006) Pneumococcal capsular
polysaccharides conjugated to protein D for prevention of acute otitis media caused
by both *Streptococcus pneumoniae* and non-typable *Haemophilus influenzae*: a
randomised double-blind efficacy study. Lancet 367:740–748
28. Hausdorff WP, Yothers G, Dagan R, Kilpi T, Pelton SI, Cohen R, Jacobs MR, Kaplan
SL, Levy C, Lopez EL, Mason EO Jr, Syriopoulou V, Wynne B, Bryant J (2002)
Multinational study of pneumococcal serotypes causing acute otitis media in children.
Pediatr Infect Dis J 21:1008–1016

29. Vergison A, Reinert RR (2007) *Streptococcus pneumoniae* incidence in Western
Europe. Lancet Infect Dis 7:240–242

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Table 1 Sources of pneumococcal isolates from children with pneumococcal otitis media in Germany

Specimen	Number (%)
Blood	24 (4.7)
Cerebrospinal fluid	33 (6.4)
Ear (tympanocentesis)	8 (1.6)
Mastoid	3 (0.6)
Pus middle ear	13 (2.5)
Swab ear	431 (84.2)
Total	512 (100)

Table 2 Coverage of the 7-valent, 10-valent, and investigational 13-valent pneumococcal conjugate vaccines in pneumococcal acute otitis media with ruptured tympanic membrane or sepsis isolates in Germany

Age Group	Vaccine formulation			Total
	7-valent	10-valent	13-valent	
<5 years (<i>n</i> , %)	207 (60.3)	218 (63.6)	293 (85.4)	343 (100)
≥5 years (<i>n</i> , %)	71 (42.0)	90 (53.3)	140 (82.8)	169 (100)
All ages (<i>n</i> , %)	278 (54.3)	308 (60.2)	433 (84.6)	512 (100)

Table 3 Antibiotic resistance in *S. pneumoniae* isolated from patients with acute otitis media
in Germany (*n*=465)

Resistance	Penicillin G <i>n</i> (%)	Clarithromycin <i>n</i> (%)
Susceptible	406 (89.0)	349 (76.5)
Intermediate	30 (6.6)	5 (1.1)
Resistant	20 (4.4)	102 (22.4)
Total	456 (100)	456 (100)

Table 4 Characteristics of invasive pneumococcal disease in children with pneumococcal otitis media (otogenic sepsis or meningitis) in Germany ($n=33$)

Patients ($n=33$)			Susceptibility		
Age, Gender	Diagnosis (Isolate)	Serotype	E-myc	Pen G	
5 mo, ND	Otitis perforans (B)	33A	S	S	
6 mo, M	Mastoiditis (B)	23F	S	S	
2 y, F	Meningitis, mastoiditis (CSF)	24F	S	S	
9 mo, F	ND (B)	19A	R	S	
3 y, M	Pneumonia, convulsion (B)	19A	R	S	
4 mo, M	Meningitis (CSF)	19A	ND	ND	
9 mo, F	Meningitis, mastoiditis (CSF)	19A	S	S	
1 y, F	ND (B)	19F	S	S	
3 y, M	ND (B)	19F	S	I	
1 y, M	Sepsis (B)	18C	S	S	
2 y, M	Meningitis (CSF)	18C	S	S	
1 y, F	ND (B)	14	R	S	
2 y, F	Pharyngitis (B)	14	R	S	
2 y, F	Pharyngitis (B)	14	R	S	
1 y, F	Pneumonia, coxitis (B)	14	R	S	
2 y, F	High fever (B)	14	R	S	
1 y, F	Sepsis (B)	14	R	S	
1 y, M	Mastoiditis (B)	14	R	S	
1 y, F	Meningitis (B)	14	R	S	
1 y, F	ND (B)	14	S	S	
1 y, F	Meningitis (CSF)	14	S	S	
1 y, M	Meningitis (CSF)	14	S	R	
7 mo, M	ND (CSF)	14	S	S	
1 y, M	Meningitis (CSF)	14	R	S	
1 y, M	Meningitis (CSF)	14	R	S	
1 y, M	Meningitis (CSF)	10A	S	S	
11 mo, M	Recurrent otitis (B)	9N	ND	ND	
4 y, ND	Chronic otitis (B)	7F	S	S	
11 mo, M	Meningitis (CSF)	7F	S	S	
1 y, M	Meningitis (CSF)	6A	S	S	
2 y, M	Sepsis, meningitis (B)	6B	S	S	
3 y, F	ND (B)	6B	S	S	
2 y, F	Meningitis, sepsis (CSF)	4	S	S	

E-myc erythromycin, *Pen G* penicillin G, *B* blood, *CSF* cerebrospinal fluid, *S* susceptible, *R* resistant, *I* intermediate, *ND* no data

Fig. 1 Serotype Distribution for Pneumococcal OM Germany All Ages and <5 years

Fig. 2 Coverage of different pneumococcal conjugate vaccine formulations in pneumococcal strains from otitis media in Germany (children aged <5 years). Red = serotypes included in the 7-valent vaccine; yellow = additional serotypes in the 10-valent vaccine; blue = additional serotypes in the investigational 13-valent vaccine; gray = other serotypes not included in any of the three vaccines.

Figure 1
[Click here to download high resolution image](#)

Figure 2